WEKO3
アイテム
{"_buckets": {"deposit": "49ba33ec-47a1-4961-9ebc-5bcc920155f7"}, "_deposit": {"created_by": 16, "id": "15230", "owners": [16], "pid": {"revision_id": 0, "type": "depid", "value": "15230"}, "status": "published"}, "_oai": {"id": "oai:mie-u.repo.nii.ac.jp:00015230", "sets": ["1336"]}, "author_link": [], "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-07-20", "bibliographicIssueDateType": "Issued"}}]}, "item_7_date_granted_59": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2022-07-20"}]}, "item_7_degree_grantor_57": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_name": "三重大学"}], "subitem_degreegrantor_identifier": [{"subitem_degreegrantor_identifier_name": "14101", "subitem_degreegrantor_identifier_scheme": "kakenhi"}]}]}, "item_7_degree_name_56": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)"}]}, "item_7_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Ewing sarcoma is an aggressive and the second most common bone tumor in adolescent and young adult patients. The 5-year survival rate is 60–70% for localized disease but 30% for patients with metastases. Here, we aimed to identify a therapeutic target for Ewing sarcoma and evaluate antibody-based therapeutic agents using in vitro and in vivo models. We identified G protein-coupled receptor 64 (GPR64) as a therapeutic target for Ewing sarcoma via next-generation RNA-sequencing. GPR64v205 mRNA was expressed in HTB166, A673, MG63, 143B, HS-Sy II, and HT1080 cell lines as well as in Ewing sarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma, dedifferentiated liposarcoma, and synovial sarcoma tissues. GPR64 expression was observed in 62.5% of sarcoma cases and was overexpressed in 33.9% cases. GPR64-specific monoclonal antibodies were tested as near-infrared probes for in vivo imaging using subcutaneous tumor mouse xenografts. Fluorescence intensity was stronger for the AF700-labeled anti-GPR64 antibody than that for the AF700-labeled isotype control antibody. GPR64 was detected in engrafted tumors of A673, 143B, HT1080, and the epididymis but not in other resected tissues. The anti-GPR64 antibody showed excellent binding to GPR64-positive tumors but not to healthy tissues. This antibody has potential for drug delivery in the antibody-based treatment of sarcomas.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_7_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "本文/Department of Orthopedic Surgery, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan", "subitem_description_type": "Other"}, {"subitem_description": "17p", "subitem_description_type": "Other"}]}, "item_7_dissertation_number_60": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "甲医学第2141号"}]}, "item_7_publisher_30": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "三重大学"}]}, "item_7_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/cancers14030814", "subitem_relation_type_select": "DOI"}}]}, "item_7_text_31": {"attribute_name": "出版者(ヨミ)", "attribute_value_mlt": [{"subitem_text_value": "ミエダイガク"}]}, "item_7_text_63": {"attribute_name": "ノート", "attribute_value_mlt": [{"subitem_text_value": "Cancers 2022, 14, 814に掲載"}]}, "item_7_text_65": {"attribute_name": "資源タイプ(三重大)", "attribute_value_mlt": [{"subitem_text_value": "Doctoral Dissertation / 博士論文"}]}, "item_7_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakamura, Koichi", "creatorNameLang": "en"}, {"creatorName": "ナカムラ, コウイチ", "creatorNameLang": "ja-Kana"}, {"creatorName": "中村, 公一", "creatorNameLang": "ja"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2022-10-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "2022DM0712.pdf", "filesize": [{"value": "2.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "application/pdf", "size": 2000000.0, "url": {"label": "2022DM0712", "objectType": "fulltext", "url": "https://mie-u.repo.nii.ac.jp/record/15230/files/2022DM0712.pdf"}, "version_id": "9206b082-ca15-4d7f-b1ae-80a71118c966"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Ewing sarcoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "GPR64", "subitem_subject_scheme": "Other"}, {"subitem_subject": "antibody-based therapeutics", "subitem_subject_scheme": "Other"}, {"subitem_subject": "epididymis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "sarcomas", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "doctoral thesis", "resourceuri": "http://purl.org/coar/resource_type/c_db06"}]}, "item_title": "GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "16", "path": ["1336"], "permalink_uri": "http://hdl.handle.net/10076/00020848", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2022-10-24"}, "publish_date": "2022-10-24", "publish_status": "0", "recid": "15230", "relation": {}, "relation_version_is_last": true, "title": ["GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas"], "weko_shared_id": -1}
GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas
http://hdl.handle.net/10076/00020848
http://hdl.handle.net/10076/00020848052926e8-fd88-409b-af85-9c232d12c73f
名前 / ファイル | ライセンス | アクション |
---|---|---|
2022DM0712 (2.0 MB)
|
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2022-10-24 | |||||||||||
タイトル | ||||||||||||
言語 | en | |||||||||||
タイトル | GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas | |||||||||||
言語 | ||||||||||||
言語 | eng | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | Ewing sarcoma | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | GPR64 | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | antibody-based therapeutics | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | epididymis | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | sarcomas | |||||||||||
資源タイプ | ||||||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||||
資源タイプ | doctoral thesis | |||||||||||
アクセス権 | ||||||||||||
アクセス権 | open access | |||||||||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||
著者 |
中村, 公一
× 中村, 公一
|
|||||||||||
抄録 | ||||||||||||
内容記述タイプ | Abstract | |||||||||||
内容記述 | Ewing sarcoma is an aggressive and the second most common bone tumor in adolescent and young adult patients. The 5-year survival rate is 60–70% for localized disease but 30% for patients with metastases. Here, we aimed to identify a therapeutic target for Ewing sarcoma and evaluate antibody-based therapeutic agents using in vitro and in vivo models. We identified G protein-coupled receptor 64 (GPR64) as a therapeutic target for Ewing sarcoma via next-generation RNA-sequencing. GPR64v205 mRNA was expressed in HTB166, A673, MG63, 143B, HS-Sy II, and HT1080 cell lines as well as in Ewing sarcoma, undifferentiated pleomorphic sarcoma, leiomyosarcoma, dedifferentiated liposarcoma, and synovial sarcoma tissues. GPR64 expression was observed in 62.5% of sarcoma cases and was overexpressed in 33.9% cases. GPR64-specific monoclonal antibodies were tested as near-infrared probes for in vivo imaging using subcutaneous tumor mouse xenografts. Fluorescence intensity was stronger for the AF700-labeled anti-GPR64 antibody than that for the AF700-labeled isotype control antibody. GPR64 was detected in engrafted tumors of A673, 143B, HT1080, and the epididymis but not in other resected tissues. The anti-GPR64 antibody showed excellent binding to GPR64-positive tumors but not to healthy tissues. This antibody has potential for drug delivery in the antibody-based treatment of sarcomas. | |||||||||||
言語 | en | |||||||||||
内容記述 | ||||||||||||
内容記述タイプ | Other | |||||||||||
内容記述 | 本文/Department of Orthopedic Surgery, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan | |||||||||||
内容記述 | ||||||||||||
内容記述タイプ | Other | |||||||||||
内容記述 | 17p | |||||||||||
書誌情報 |
発行日 2022-07-20 |
|||||||||||
DOI | ||||||||||||
識別子タイプ | DOI | |||||||||||
関連識別子 | 10.3390/cancers14030814 | |||||||||||
フォーマット | ||||||||||||
内容記述タイプ | Other | |||||||||||
内容記述 | application/pdf | |||||||||||
著者版フラグ | ||||||||||||
出版タイプ | VoR | |||||||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||
出版者 | ||||||||||||
出版者 | 三重大学 | |||||||||||
出版者(ヨミ) | ||||||||||||
ミエダイガク | ||||||||||||
学位名 | ||||||||||||
学位名 | 博士(医学) | |||||||||||
学位授与機関 | ||||||||||||
学位授与機関識別子Scheme | kakenhi | |||||||||||
学位授与機関識別子 | 14101 | |||||||||||
学位授与機関名 | 三重大学 | |||||||||||
学位授与年月日 | ||||||||||||
学位授与年月日 | 2022-07-20 | |||||||||||
学位授与番号 | ||||||||||||
学位授与番号 | 甲医学第2141号 | |||||||||||
ノート | ||||||||||||
Cancers 2022, 14, 814に掲載 | ||||||||||||
資源タイプ(三重大) | ||||||||||||
Doctoral Dissertation / 博士論文 |